Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.65 |
| ▸ | DRD4 | P21917 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | LTA4H | P09960 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1837149 | 0.94 | FFAR1 (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1836368 | 0.93 | FFAR1 (0.64) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL2091234 | 0.93 | FFAR1 (0.64) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL28807540 | 0.92 | FFAR1 (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL1833211 | 0.90 | LMNA (0.68) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL839323 | 0.86 | DRD2 (0.71) | FFAR1DRD4DRD2DRD3S1PR1 | |
| SCHEMBL27980904 | 0.85 | FFAR1 (0.59) | LMNAPTGS1SLC6A2PTGS2SLC6A3 | |
| SCHEMBL27980780 | 0.85 | FFAR1 (0.59) | LMNAPTGS1SLC6A2PTGS2SLC6A3 | |
| SCHEMBL10792214 | 0.84 | LMNA (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL24041796 | 0.83 | FFAR1 (0.68) | FFAR1DRD4DRD2DRD3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002679-A1 | COMPOUND AND LIQUID CRYSTAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2023-01-05 | — | — | US | disclosed |
| EP-3838892-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2022-10-12 | — | — | EP | disclosed |
| EP-3293173-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2021-07-28 | — | — | EP | disclosed |
| EP-3838892-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Kabushiki Kaisha (JP) | 2021-06-23 | — | — | EP | disclosed |
| EP-2980066-B1 | METHOD FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2021-04-21 | — | — | EP | disclosed |
| CN-107266338-B | The manufacturing method of isocyanates | 旭化成株式会社 | 2019-10-11 | — | — | CN | disclosed |
| EP-3153499-B1 | METHOD FOR PRODUCING N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-2895456-B1 | AMINOETHYLATION PROCESS FOR PRODUCING ARYLOXYALKYLENE AMINE COMPOUNDS | CHEVRON ORONITE CO (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3293173-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Kabushiki Kaisha (JP) | 2018-03-14 | — | — | EP | disclosed |
| CN-105102422-B | Method for producing isocyanate | 旭化成株式会社 | 2018-01-09 | — | — | CN | disclosed |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2322504-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | Asahi Kasei Chemicals Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-4538164-A | LEUCO DYE, HYDROXYPHENOLIC ETHER DEVELOPER, OIL ABSORBING FILLER | RICOH CO., LTD. (JP) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | LMNA 1776/4885CYP1A2 1325/4885PTGS1 1737/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | LMNA 4594/4885CYP1A2 420/4885PTGS1 2872/4885 |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | LMNA 2324/4885CYP1A2 121/4885PTGS1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.